MaxCyte Valuation

Is MYE0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MYE0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MYE0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MYE0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MYE0?

Key metric: As MYE0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MYE0. This is calculated by dividing MYE0's market cap by their current revenue.
What is MYE0's PS Ratio?
PS Ratio	7.9x
Sales	US$45.60m
Market Cap	US$360.30m

MYE0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.1x
Enterprise Value/EBITDA	-5.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MYE0's PS Ratio compare to its peers?

The above table shows the PS ratio for MYE0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
EVT Evotec	2.1x	12.1%	€1.6b
GXI Gerresheimer	1.3x	10.3%	€2.6b
1SXP SCHOTT Pharma KGaA	4.3x	10.7%	€4.1b
SRT3 Sartorius	4.5x	9.3%	€13.6b
MYE0 MaxCyte	7.9x	20.5%	€286.9m

Price-To-Sales vs Peers: MYE0 is expensive based on its Price-To-Sales Ratio (7.9x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does MYE0's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MYE0 is expensive based on its Price-To-Sales Ratio (7.9x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is MYE0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MYE0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.9x
Fair PS Ratio	3.4x

Price-To-Sales vs Fair Ratio: MYE0 is expensive based on its Price-To-Sales Ratio (7.9x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MYE0 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€3.18	€7.60 +139.0%	20.3%	€9.14	€6.06	n/a	2
Nov ’25	€3.34	€7.60 +127.5%	20.7%	€9.17	€6.02	n/a	2
Oct ’25	€3.42	€6.38 +86.6%	39.8%	€8.92	€3.84	n/a	2
Sep ’25	€3.60	€6.38 +77.3%	39.8%	€8.92	€3.84	n/a	2
Aug ’25	€4.06	€6.47 +59.3%	40.8%	€9.11	€3.83	n/a	2
Jul ’25	€3.58	€6.44 +79.8%	40.1%	€9.02	€3.85	n/a	2
Jun ’25	€4.14	€6.42 +55.0%	40.4%	€9.01	€3.82	n/a	2
Oct ’24	€2.78	€8.58 +208.5%	6.5%	€9.13	€8.02	€3.42	2
Sep ’24	€3.34	€8.58 +156.8%	6.5%	€9.13	€8.02	€3.60	2
Aug ’24	€4.04	€9.80 +142.6%	7.0%	€10.48	€9.12	€4.06	2
Jul ’24	€4.10	€9.96 +142.9%	7.6%	€10.72	€9.20	€3.58	2
Jun ’24	€3.80	€9.81 +158.3%	7.8%	€10.58	€9.04	€4.14	2
May ’24	€4.34	€11.11 +156.1%	6.5%	€11.84	€10.39	€3.32	2
Apr ’24	€4.28	€11.11 +159.7%	6.5%	€11.84	€10.39	€4.00	2
Mar ’24	€4.24	€11.30 +166.4%	3.2%	€11.65	€10.94	€4.06	2
Feb ’24	€5.35	€11.30 +111.1%	3.2%	€11.65	€10.94	€4.48	2
Jan ’24	€4.98	€11.49 +130.8%	2.5%	€11.78	€11.21	€3.90	2
Dec ’23	€5.70	€11.55 +102.7%	3.6%	€11.97	€11.13	€4.20	2
Nov ’23	€7.00	€11.97 +71.0%	11.1%	€13.30	€10.65	€2.70	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.55

2.0%

95.6%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.20

5.0%

23.7%

Pharming Group

€478.2m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

1.8%

-31.2%